MRC Human Genetics Unit at the University of Edinburgh

Belkins
The MRC Human Genetics Unit discovers how changes in our DNA impact our lives. We combine the latest computational and experimental technologies to investigate how our genomes work to control the function of molecules, cells and tissues in people and populations. For more than half a century our research has been dedicated to understanding human genetic disease. Today we continue to apply our clinical and scientific expertise, harnessing the power of complex data, to improve health, and the lives of patients and their families.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

MRNA VICTORIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO GROW THE BIOECONOMY & INTERNATIONAL BIOSECURITY CAPABILITIES

Ginkgo Bioworks, mRNA Victoria | November 18, 2021

news image

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first ...

Read More

CELL AND GENE THERAPY

DISCOVERY LIFE SCIENCES LAUNCHES GMP COMPLIANT DISCOVERY LEUKOPAKS™ TO ACCELERATE RESEARCH AND DEVELOPMENT OF CELL AND GENE THERAPIES

Discovery Life Sciences | October 28, 2020

news image

Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announces the launch of GMP-compliant Discovery Leukopaks™ and other cell-based products for use in human cell and gene therapy research, development and manufacturing programs. Cell and gene therapies have revolutionized treatment approaches to cancer and other complex diseases. Acceleration of the manufacturing and development of these novel thera...

Read More

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

news image

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More

MEDICAL

LILLY, VIR BIOTECHNOLOGY AND GSK COLLABORATES TO EVALUATE A COMBINATION OF TWO COVID-19 THERAPIES IN LOW-RISK PATIENTS

Lilly | January 28, 2021

news image

Eli Lilly and Company, Vir Biotechnology, Inc. also, GlaxoSmithKline plc declares a collaboration effort to assess a mix of two COVID-19 therapies in low-risk patients with mild to direct COVID-19. Lilly has extended its progressing BLAZE-4 trial to assess the organization of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (otherwise called GSK4182136) 500mg, two killing antibodies that quandary to various epitopes of the SARS-CoV-2 spike protein. This unique collaboration effort denotes the first ...

Read More
news image

CELL AND GENE THERAPY

MRNA VICTORIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO GROW THE BIOECONOMY & INTERNATIONAL BIOSECURITY CAPABILITIES

Ginkgo Bioworks, mRNA Victoria | November 18, 2021

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first ...

Read More
news image

CELL AND GENE THERAPY

DISCOVERY LIFE SCIENCES LAUNCHES GMP COMPLIANT DISCOVERY LEUKOPAKS™ TO ACCELERATE RESEARCH AND DEVELOPMENT OF CELL AND GENE THERAPIES

Discovery Life Sciences | October 28, 2020

Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announces the launch of GMP-compliant Discovery Leukopaks™ and other cell-based products for use in human cell and gene therapy research, development and manufacturing programs. Cell and gene therapies have revolutionized treatment approaches to cancer and other complex diseases. Acceleration of the manufacturing and development of these novel thera...

Read More
news image

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More
news image

MEDICAL

LILLY, VIR BIOTECHNOLOGY AND GSK COLLABORATES TO EVALUATE A COMBINATION OF TWO COVID-19 THERAPIES IN LOW-RISK PATIENTS

Lilly | January 28, 2021

Eli Lilly and Company, Vir Biotechnology, Inc. also, GlaxoSmithKline plc declares a collaboration effort to assess a mix of two COVID-19 therapies in low-risk patients with mild to direct COVID-19. Lilly has extended its progressing BLAZE-4 trial to assess the organization of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (otherwise called GSK4182136) 500mg, two killing antibodies that quandary to various epitopes of the SARS-CoV-2 spike protein. This unique collaboration effort denotes the first ...

Read More